Viridian Therapeutics, Inc. (VRDN)
19.03
-0.53
(-2.71%)
USD |
NASDAQ |
Oct 16, 16:00
18.76
-0.27
(-1.42%)
After-Hours: 20:00
Viridian Therapeutics Research and Development Expense (Annual) : 338.47M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 338.47M |
| December 31, 2024 | 237.71M |
| December 31, 2023 | 159.24M |
| December 31, 2022 | 100.64M |
| December 31, 2021 | 56.77M |
| December 31, 2020 | 27.76M |
| December 31, 2019 | 34.51M |
| Date | Value |
|---|---|
| December 31, 2018 | 30.42M |
| December 31, 2017 | 19.62M |
| December 31, 2016 | 13.69M |
| December 31, 2015 | 1.002M |
| December 31, 2014 | 0.293M |
| December 31, 2013 | 0.0968M |
| December 31, 2012 | 0.2254M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.754B |
| TG Therapeutics, Inc. | 160.22M |
| Travere Therapeutics, Inc. | 206.01M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |